PA · ALINT.PA
IntegraGen S.A.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Évry 91000
- Website
- integragen.com
Price · as of 2024-12-31
$0.17
Market cap 1.14M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $69.08 | +40,775.74% |
| Intrinsic Value(DCF) | $0.20 | +18.34% |
| Graham-Dodd Method(GD) | $0.07 | -57.99% |
| Graham Formula(GF) | $0.80 | +375.15% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | $6.75 | ||||
| 2013 | $7.96 | $53.08 | $0.00 | $0.00 | $0.00 |
| 2014 | $5.89 | $340.27 | $0.38 | $0.00 | $0.00 |
| 2015 | $3.23 | $31.09 | $0.00 | $0.00 | $0.00 |
| 2016 | $3.02 | $23.34 | $0.00 | $0.00 | $0.00 |
| 2017 | $2.37 | $26.81 | $0.21 | $0.00 | $0.00 |
| 2018 | $1.10 | $22.43 | $0.19 | $0.00 | $0.00 |
| 2019 | $1.20 | $50.86 | $1.40 | $0.17 | $0.00 |
| 2020 | $2.04 | $41.51 | $1.30 | $0.04 | $0.00 |
| 2021 | $1.09 | $51.53 | $19.06 | $0.34 | $0.08 |
| 2022 | $1.29 | $44.73 | $22.83 | $0.33 | $0.00 |
| 2023 | $0.68 | $1,443.10 | $1.45 | $0.17 | $0.00 |
| 2024 | $0.50 | $69.08 | $0.00 | $0.07 | $0.80 |
AI valuation
Our deep-learning model estimates IntegraGen S.A.'s (ALINT.PA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $69.08
- Current price
- $0.17
- AI upside
- +40,775.74%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.20
+18.34% upside
Graham-Dodd
$0.07
-57.99% upside
Graham Formula
$0.80
+375.15% upside
About IntegraGen S.A.
IntegraGen SA provides human genome analysis services for academic researcher and life sciences companies in France. Its genomic services include transcriptomics, epigenomics, DNA sequencing, NGS testing for cancer research, and SNP genotyping. The company offers clinical research services, such as clinical grade sequencing and pharmacogenomics; basic and human genetic research; agrigenomic services, including crop and livestock genotyping and high-throughput sequencing for crops and livestock; and microbial genomics services comprising whole-genome microbial sequencing and microbial transcriptomics. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing into a molecular report for translational and clinical research use; SIRIUS, a cloud-based software tool that enables researchers to analyze whole genome, whole exome, and gene panel sequencing data; Galileo, a cloud-based app for dynamic exporation of RNA-Seq expression data; and GeCo, a genomic consulting service that offers researchers with access to biostatistics and bioanalytics experts. IntegraGen SA was founded in 2000 and is headquartered in Évry, France. IntegraGen SA is a subsidiary of OncoDNA SA.
- CEO
- Berengere Genin
- Employees
- 44
- Beta
- 0.48
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.20 ÷ $0.17) − 1 = +18.34% (DCF, example).